Literature DB >> 15038993

P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia.

Marina Myles-Worsley1, Lisa Ord, Francisca Blailes, Hilda Ngiralmau, Robert Freedman.   

Abstract

BACKGROUND: Gating or inhibition of the P50 auditory evoked potential is a heritable neurobiological trait that has shown strong potential to serve as an endophenotype for schizophrenia. P50 sensory gating deficits have been found repeatedly in schizophrenic patients and in their unaffected first-degree relatives. P50 sensory gating has not yet been studied in high-risk (HR) offspring nor in prodromal adolescents.
METHODS: A paired-stimulus auditory event-related potential paradigm was used to examine P50 sensory gating in 44 genetically HR adolescent offspring and 43 clinically HR prodromal adolescents with the same low genetic liability as a comparison group of 39 normal adolescents.
RESULTS: Auditory sensory gating, as measured by the P50 ratio, was impaired in both genetically HR offspring and also in the clinically HR prodromal adolescents with no close affected relatives. In the genetically HR group, abnormal P50 sensory gating was found only in offspring who met criteria for the schizophrenia prodrome.
CONCLUSIONS: Our findings suggest that P50 deficits are associated with the presence of prodromal symptoms, regardless of genetic risk. The results are consistent with the hypothesis that genetic liability in HR offspring increases risk for prodromal symptoms, and prodromal symptoms, in turn, increase risk for impaired sensory gating.

Entities:  

Mesh:

Year:  2004        PMID: 15038993     DOI: 10.1016/j.biopsych.2003.12.006

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  25 in total

Review 1.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

Review 2.  Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.

Authors:  David Potter; Ann Summerfelt; James Gold; Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

3.  Neurocognitive deficits in the (putative) prodrome and first episode of psychosis.

Authors:  A D Eastvold; R K Heaton; K S Cadenhead
Journal:  Schizophr Res       Date:  2007-04-30       Impact factor: 4.939

Review 4.  How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia?

Authors:  Katherine Seeber; Kristin S Cadenhead
Journal:  Curr Psychiatry Rep       Date:  2005-03       Impact factor: 5.285

5.  Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia.

Authors:  Elena Magno; Sherlyn Yeap; Jogin H Thakore; Hugh Garavan; Pierfilippo De Sanctis; John J Foxe
Journal:  Biol Psychiatry       Date:  2008-05-09       Impact factor: 13.382

6.  Progress in the Prospective Study of the Schizophrenia Prodrome.

Authors:  Emery J Fu; Kristin S Cadenhead
Journal:  Curr Psychos Ther Rep       Date:  2005-12-01

Review 7.  Atypical scanpaths in schizophrenia: evidence of a trait- or state-dependent phenomenon?

Authors:  Sara A Beedie; Philip J Benson; David M St Clair
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

Review 8.  Electroencephalography and Event-Related Potential Biomarkers in Individuals at Clinical High Risk for Psychosis.

Authors:  Holly K Hamilton; Alison K Boos; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2020-04-14       Impact factor: 13.382

9.  Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia.

Authors:  Erin A Hazlett; Ethan G Rothstein; Rui Ferreira; Jeremy M Silverman; Larry J Siever; Ann Olincy
Journal:  Schizophr Res       Date:  2014-12-05       Impact factor: 4.939

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.